Selank

Research-Grade

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from tuftsin — a naturally occurring tetrapeptide fragment of the heavy chain of immunoglobulin G — with an added Pro-Gly-Pro tripeptide tail that confers enzymatic stability and extends its biological half-life. It was developed in the late 1990s by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, specifically to create an anxiolytic agent without the sedation, cognitive impairment, tolerance, or physical dependence associated with benzodiazepines. The anxiolytic mechanism operates through allosteric modulation of the GABA-A receptor complex (enhancing inhibitory neurotransmission without directly binding the benzodiazepine site), stabilization of enkephalin metabolism (prolonging endogenous opioid peptide activity), upregulation of BDNF expression (supporting neuroplasticity), and modulation of serotonergic tone. This multi-target profile produces anxiolysis that is qualitatively distinct from benzodiazepines — reducing anxiety without sedation, motor impairment, or amnesia. Selank received regulatory approval in Russia as a prescription medication for generalized anxiety disorder and neurasthenia, and has been marketed there since the early 2000s as an intranasal spray formulation. Intranasal delivery is essential because the peptide does not survive gastrointestinal digestion, and the nasal mucosa provides direct access to the central nervous system via olfactory nerve pathways, bypassing the blood-brain barrier. Intranasal bioavailability is sufficient to produce anxiolytic effects within 15-30 minutes of administration, with a duration of approximately 3-4 hours per dose. The Russian clinical literature reports consistent efficacy across small human cohorts with no evidence of tolerance, dependence, or withdrawal — a critical advantage over benzodiazepines for chronic anxiety management. However, Western regulatory recognition remains absent; controlled clinical trials are predominantly published in Russian-language journals and have not been independently replicated by Western research groups. Selank retains some immunomodulatory activity from its tuftsin parent structure, including effects on IL-6 expression and T-helper cell balance, which some practitioners consider a secondary benefit during stress-related immune suppression.